C-Path and Global Partners launch Ataxia Consortium

(Critical Path Institute (C-Path)) Critical Path Institute today announced the launch of the Critical Path to Therapeutics for the Ataxias Consortium, a public-private partnership focused on optimizing clinical trials for inherited ataxias. CPTA is a collaborative effort between C-Path, Ataxia Global Initiative, the National Ataxia Foundation, Ataxia UK and key partners in the industry and academic research communities, including Biohaven Pharmaceuticals, Ionis Pharmaceuticals, Roche Pharmaceuticals, Servier Group, Triplet Therapeutics, uniQure, and Vico Therapeutics.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news